These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

533 related items for PubMed ID: 15786866

  • 1. Antibody recognition of synthetic peptides mimicking immunodominant regions of HIV-1 p24 and p17 proteins.
    Lottersberger J, Salvetti JL, Beltramini LM, Tonarelli G.
    Rev Argent Microbiol; 2004; 36(4):151-7. PubMed ID: 15786866
    [Abstract] [Full Text] [Related]

  • 2. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
    Kmieciak D, Bolesta E, Naito T, Gzyl J, Kaneko Y, Kozbor D.
    J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
    [Abstract] [Full Text] [Related]

  • 3. Preclinical studies on immunogenicity of the HIV-1 p17-based synthetic peptide AT20-KLH.
    Fiorentini S, Marini E, Bozzo L, Trainini L, Saadoune L, Avolio M, Pontillo A, Bonfanti C, Sarmientos P, Caruso A.
    Biopolymers; 2004; 76(4):334-43. PubMed ID: 15386266
    [Abstract] [Full Text] [Related]

  • 4. Gag-derived proteins of HIV-1 isolates from Indian patients: cloning, expression, and purification of p17 of B- and C-subtypes.
    Gupta S, Arora K, Gupta A, Chaudhary VK.
    Protein Expr Purif; 2001 Apr; 21(3):378-85. PubMed ID: 11281711
    [Abstract] [Full Text] [Related]

  • 5. Immunization of human HIV-seronegative volunteers with recombinant p17/p24:Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses.
    Martin SJ, Vyakarnam A, Cheingsong-Popov R, Callow D, Jones KL, Senior JM, Adams SE, Kingsman AJ, Matear P, Gotch FM.
    AIDS; 1993 Oct; 7(10):1315-23. PubMed ID: 8267904
    [Abstract] [Full Text] [Related]

  • 6. Differential narrow focusing of immunodominant human immunodeficiency virus gag-specific cytotoxic T-lymphocyte responses in infected African and caucasoid adults and children.
    Goulder PJ, Brander C, Annamalai K, Mngqundaniso N, Govender U, Tang Y, He S, Hartman KE, O'Callaghan CA, Ogg GS, Altfeld MA, Rosenberg ES, Cao H, Kalams SA, Hammond M, Bunce M, Pelton SI, Burchett SA, McIntosh K, Coovadia HM, Walker BD.
    J Virol; 2000 Jun; 74(12):5679-90. PubMed ID: 10823876
    [Abstract] [Full Text] [Related]

  • 7. Cytolytic T lymphocytes (CTLs) from HIV-1 subtype C-infected Indian patients recognize CTL epitopes from a conserved immunodominant region of HIV-1 Gag and Nef.
    Thakar MR, Bhonge LS, Lakhashe SK, Shankarkumar U, Sane SS, Kulkarni SS, Mahajan BA, Paranjape RS.
    J Infect Dis; 2005 Sep 01; 192(5):749-59. PubMed ID: 16088824
    [Abstract] [Full Text] [Related]

  • 8. Decline in CTL and antibody responses to HIV-1 p17 and p24 antigens in HIV-1-infected hemophiliacs irrespective of disease progression. A 5-year follow-up study.
    O'Toole CM, Lowdell MW, Chargelegue D, Colvin BT.
    AIDS Res Hum Retroviruses; 1992 Aug 01; 8(8):1361-8. PubMed ID: 1281655
    [Abstract] [Full Text] [Related]

  • 9. Fine specificity of IgG subclass response to group antigens in HIV-1-infected patients.
    Broliden PA, Morfeldt-Månsson L, Rosen J, Jondal M, Wahren B.
    Clin Exp Immunol; 1989 May 01; 76(2):216-21. PubMed ID: 2503275
    [Abstract] [Full Text] [Related]

  • 10. Immune responses to six synthetic peptides of capsid protein with sera from HIV-1 infected individuals.
    Liu G, Yang L, Wang J, Zhang G, Chen X, Zheng Y.
    Cell Mol Immunol; 2005 Aug 01; 2(4):289-93. PubMed ID: 16274627
    [Abstract] [Full Text] [Related]

  • 11. Immunodominant epitopes of HIV-1 p17 and p24.
    Graham S, Follett EA, Wallace L, Desselberger U, Marsden HS.
    AIDS Res Hum Retroviruses; 1992 Oct 01; 8(10):1781-8. PubMed ID: 1280955
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Evaluation of synthetic peptides for the detection of antibodies against human immunodeficiency virus].
    Lottersberger J, Salvetti JL, Tonarelli G.
    Rev Argent Microbiol; 2003 Oct 01; 35(3):149-55. PubMed ID: 14587377
    [Abstract] [Full Text] [Related]

  • 15. Molecular dynamics analysis of HIV-1 matrix protein: clarifying differences between crystallographic and solution structures.
    Verli H, Calazans A, Brindeiro R, Tanuri A, Guimarães JA.
    J Mol Graph Model; 2007 Jul 01; 26(1):62-8. PubMed ID: 17067836
    [Abstract] [Full Text] [Related]

  • 16. Use of the presence of anti-protein gag antibodies as an evolution marker of HIV infection.
    Neguţ EA, Usein CR, Sfartz S, Zugun-Eloae F.
    Roum Arch Microbiol Immunol; 1999 Jul 01; 58(2):131-46. PubMed ID: 11845452
    [Abstract] [Full Text] [Related]

  • 17. Temporal analysis of the antibody response to HIV envelope protein in HIV-infected laboratory workers.
    Pincus SH, Messer KG, Nara PL, Blattner WA, Colclough G, Reitz M.
    J Clin Invest; 1994 Jun 01; 93(6):2505-13. PubMed ID: 7515393
    [Abstract] [Full Text] [Related]

  • 18. Cross-reactivity of anti-HIV-1-p17-derivative peptide (P30-52) antibody to Env V3 peptide.
    Ota A, Tanaka-Taya K, Ueda S.
    Hybridoma; 1999 Apr 01; 18(2):149-57. PubMed ID: 10380014
    [Abstract] [Full Text] [Related]

  • 19. Reactivities of HIV-1 gag-derived peptides with antibodies of HIV-1-infected and uninfected humans.
    Haist S, März J, Wolf H, Modrow S.
    AIDS Res Hum Retroviruses; 1992 Nov 01; 8(11):1909-17. PubMed ID: 1489579
    [Abstract] [Full Text] [Related]

  • 20. Prevalence and persistence of antibody titers to recombinant HIV-1 core and matrix proteins in HIV-1 infection.
    Janvier B, Mallet F, Cheynet V, Dalbon P, Vernet G, Besnier JM, Choutet P, Goudeau A, Mandrand B, Barin F.
    J Acquir Immune Defic Syndr (1988); 1993 Aug 01; 6(8):898-903. PubMed ID: 8315575
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.